CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

Half advice show. Half survival guide. Half absurdity-fest. (Wait, how does this work again? We're not numbers people.) Each episode, we answer all your burning questions, from how to survive a public ...

SYDNEY, Feb 11 (Reuters) - CSL Ltd (CSL.AX), opens new tab on Wednesday reported an 81% drop in first‑half profit, knocked by weaker blood plasma product and vaccine sales and one-off charges, a day ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

CSL Ltd. is out-licensing its interleukin-6 (IL-6) monoclonal antibody, clazakizumab, to Eli Lilly and Co. in a deal that brings CSL $100 million in up-front fees. A CSL spokesperson told BioWorld the ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection. Australia-based CSL picked ...

Feb 18 (Reuters) - Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co, granting it certain rights to develop and commercialise clazakizumab, ...

Should you be buying CSL right now? ProPicks AI evaluates CSL alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it ...

Feb 18 (Reuters) - Australia's CSL said on Wednesday it had entered into ‌an exclusive licensing agreement with ‌Eli Lilly and Co, granting it certain rights to develop and commercialise clazakizumab, ...

Board director Andrew Stevens says the gap at the top end of town will never close unless executive roles can be redesigned to better suit women.